BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Citrome L. Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2013;67:1089-1104. [PMID: 24016209 DOI: 10.1111/ijcp.12298] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Köhler S, Cierpinsky K, Kronenberg G, Adli M. The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants. J Psychopharmacol 2016;30:13-22. [DOI: 10.1177/0269881115609072] [Cited by in Crossref: 73] [Cited by in F6Publishing: 46] [Article Influence: 14.6] [Reference Citation Analysis]
2 Citrome L. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2014;68:60-82. [PMID: 24165478 DOI: 10.1111/ijcp.12350] [Cited by in Crossref: 45] [Cited by in F6Publishing: 23] [Article Influence: 5.6] [Reference Citation Analysis]
3 Scott LJ. Levomilnacipran Extended-Release: A Review of Its Use in Adult Patients with Major Depressive Disorder. CNS Drugs 2014;28:1071-82. [DOI: 10.1007/s40263-014-0203-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
4 Paolucci S. Advances in antidepressants for treating post-stroke depression. Expert Opin Pharmacother 2017;18:1011-7. [PMID: 28535081 DOI: 10.1080/14656566.2017.1334765] [Cited by in Crossref: 39] [Cited by in F6Publishing: 25] [Article Influence: 9.8] [Reference Citation Analysis]
5 Sheehan DV, Nakagome K, Asami Y, Pappadopulos EA, Boucher M. Restoring function in major depressive disorder: A systematic review. J Affect Disord 2017;215:299-313. [PMID: 28364701 DOI: 10.1016/j.jad.2017.02.029] [Cited by in Crossref: 52] [Cited by in F6Publishing: 33] [Article Influence: 13.0] [Reference Citation Analysis]
6 Citrome L. Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of Affective Disorders 2016;196:225-33. [DOI: 10.1016/j.jad.2016.02.042] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 6.2] [Reference Citation Analysis]
7 Khoo SY, Brown RM. Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA? CNS Drugs 2014;28:713-30. [PMID: 24942635 DOI: 10.1007/s40263-014-0179-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
8 Palmer EC, Binns LN, Carey H. Levomilnacipran: A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder. Ann Pharmacother 2014;48:1030-9. [DOI: 10.1177/1060028014535074] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
9 Wang HR, Woo YS, Ahn HS, Ahn IM, Kim HJ, Bahk WM. Can Atypical Antipsychotic Augmentation Reduce Subsequent Treatment Failure More Effectively Among Depressed Patients with a Higher Degree of Treatment Resistance? A Meta-Analysis of Randomized Controlled Trials. Int J Neuropsychopharmacol 2015;18:pyv023. [PMID: 25770098 DOI: 10.1093/ijnp/pyv023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
10 Xue W, Fu T, Zheng G, Tu G, Zhang Y, Yang F, Tao L, Yao L, Zhu F. Recent Advances and Challenges of the Drugs Acting on Monoamine Transporters. CMC 2020;27:3830-76. [DOI: 10.2174/0929867325666181009123218] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
11 Asnis GM, Henderson MA. Levomilnacipran for the treatment of major depressive disorder: a review. Neuropsychiatr Dis Treat 2015;11:125-35. [PMID: 25657584 DOI: 10.2147/NDT.S54710] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 2.2] [Reference Citation Analysis]
12 Shi Y, Gao Q, Xu S. Chiral Bidentate Boryl Ligand Enabled Iridium-Catalyzed Enantioselective C(sp 3 )–H Borylation of Cyclopropanes. J Am Chem Soc 2019;141:10599-604. [DOI: 10.1021/jacs.9b04549] [Cited by in Crossref: 27] [Cited by in F6Publishing: 12] [Article Influence: 13.5] [Reference Citation Analysis]
13 Sanfilippo C, Nicolosi G, Patti A. Milnacipran as a challenging example of aminomethyl substrate for lipase-catalyzed kinetic resolution. Journal of Molecular Catalysis B: Enzymatic 2014;104:82-6. [DOI: 10.1016/j.molcatb.2014.03.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
14 Lahijani SC, Harris KA. Medical Complications of Psychiatric Treatment: An Update. Crit Care Clin 2017;33:713-34. [PMID: 28601142 DOI: 10.1016/j.ccc.2017.03.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
15 Ball S, Dellva MA, D'Souza DN, Marangell LB, Russell JM, Goldberger C. A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment. J Affect Disord 2014;167:215-23. [PMID: 24995890 DOI: 10.1016/j.jad.2014.06.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
16 Patel K, Abdool PS, Rajji TK, Mulsant BH. Pharmacotherapy of major depression in late life: what is the role of new agents? Expert Opinion on Pharmacotherapy 2017;18:599-609. [DOI: 10.1080/14656566.2017.1308484] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
17 Bruno A, Morabito P, Spina E, Muscatello MR. The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review. Curr Neuropharmacol 2016;14:191-9. [PMID: 26572745 DOI: 10.2174/1570159x14666151117122458] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 2.4] [Reference Citation Analysis]
18 Gill H, Gill B, El‐halabi S, Chen‐li D, Lipsitz O, Rosenblat JD, Van Rheenen TE, Rodrigues NB, Mansur RB, Majeed A, Lui LMW, Nasri F, Lee Y, Mcintyre RS. Antidepressant Medications and Weight Change: A Narrative Review. Obesity 2020;28:2064-72. [DOI: 10.1002/oby.22969] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
19 Drobnis EZ, Nangia AK. Psychotropics and Male Reproduction. Adv Exp Med Biol 2017;1034:63-101. [PMID: 29256128 DOI: 10.1007/978-3-319-69535-8_8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
20 Citrome L. Vilazodone, levomilnacipran and vortioxetine for major depressive disorder: the 15-min challenge to sort these agents out. Int J Clin Pract 2015;69:151-5. [DOI: 10.1111/ijcp.12620] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]